COVID-19 therapy and vaccination: a clinical narrative review

COVID-19 therapy and vaccination: a clinical narrative review

The SARS-CoV-2 pandemic is the most globally impacting health issue our world has faced over the last century. As of January 7, 2022, around 300 million cases have been reported worldwide, with over 5 million deaths. The SARS-CoV-2 infection causes a hyperactive host immune response leading to an ex...

Full description

Bibliographic Details
Main Authors:	Siddharth Chinta, Miguel Rodriguez-Guerra, Mohammed Shaban, Neelanjana Pandey, Maria Jaquez-Duran, Timothy J Vittorio
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2023-02-01
Series:	Drugs in Context
Subjects:	convalescent plasma covid-19 eculizumab immunoglobulins neutralizing igg1 monoclonal antibodies remdesivir sars-cov-2 steroids tocilizumab
Online Access:	https://www.drugsincontext.com/covid-19-therapy-and-vaccination-a-clinical-narrative-review/

Similar Items

Current treatment in COVID-19 disease: a rapid review
by: Miguel Rodriguez-Guerra, et al.
Published: (2021-01-01)

Remdesivir effects on COVID-19 infection in adult patients
by: Zena Hasan Sahib, et al.
Published: (2022-01-01)

Potential Immunological Treatments in COVID-19 Patients
by: Muhammet Mesut Nezir Engin, et al.
Published: (2021-04-01)

Speculations of Immunotherapy in COVID-19 Patients with Practical Applications During Childhood and Pregnancy
by: Hayder Al-Momen, et al.
Published: (2020-07-01)

Severity of Coronavirus Disease 2019 in Patients with Cancer
by: Zahraa Qusairy, et al.
Published: (2020-12-01)

Plasma therapy: a passive resistance against the deadliest
by: Anita Hansda, et al.
Published: (2022-04-01)

Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020
by: Yajie Yuan, et al.
Published: (2021-03-01)

Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis
by: Massimo Franchini, et al.
Published: (2024-02-01)

Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia
by: Emanuele Palomba, et al.
Published: (2021-09-01)

Convalescent plasma: A potential therapeutic option for COVID-19 patients
by: Swee Li Ng, et al.
Published: (2020-01-01)

Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study
by: Luther A. Bartelt, et al.
Published: (2022-10-01)

Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis
by: Sultan Ayoub Meo, et al.
Published: (2020-10-01)

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
by: Daniele Focosi, et al.
Published: (2023-08-01)

Antiviral therapy of coronavirus disease 2019 (COVID-19)
by: Pao-Yu Chen, et al.
Published: (2024-01-01)

Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
by: Llipsy Santiago, et al.
Published: (2021-03-01)

To which extent a convalescent plasma therapy could be a benefit for COVID-19 patients?
by: Abdelmonem Ali, et al.
Published: (2020-11-01)

Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates
by: Günalp Uzun, et al.
Published: (2023-06-01)

Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
by: Massimo Franchini, et al.
Published: (2024-02-01)

Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
by: Meiyu Wang, et al.
Published: (2022-12-01)

A Descriptive, Retrospective Analysis of COVID-19 Passive Antibody Therapy and Its Effects on Morbidity and Mortality in Patients Receiving B-Cell-Depleting Therapies
by: Sonia Gentile, et al.
Published: (2024-02-01)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
by: Daniele Focosi, et al.
Published: (2023-02-01)

SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening
by: Cristina Adriana Dehelean, et al.
Published: (2020-07-01)

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report
by: Jonathon Anderson, et al.
Published: (2020-07-01)

Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients
by: Laura Thümmler, et al.
Published: (2022-12-01)

Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects
by: Latha Dulipsingh, et al.
Published: (2023-06-01)

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
by: Daniele Focosi, et al.
Published: (2021-02-01)

Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial
by: Yanet Ventura-Enríquez, et al.
Published: (2022-11-01)

Virus specific antibody - based remedies for the urgent prevention and treatment of Ebola virus disease
by: T E Sizikova, et al.
Published: (2019-11-01)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
by: Daniele Focosi, et al.
Published: (2022-10-01)

Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases
by: Marijn Thijssen, et al.
Published: (2020-11-01)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
by: Xun Wang, et al.
Published: (2022-12-01)

Clinical Management of COVID-19: A Review of Pharmacological Treatment Options
by: Ashli M. Heustess, et al.
Published: (2021-05-01)

Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma
by: Thomas P. Thomopoulos, et al.
Published: (2021-09-01)

Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients
by: MEENU BAJPAI, et al.
Published: (2022-09-01)

Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia
by: Nina Nurarifah, et al.
Published: (2021-11-01)

Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report
by: Genni Casarola, et al.
Published: (2021-11-01)

Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses
by: Yi-Chan J. Lin, et al.
Published: (2022-10-01)

Updated mini-review of the chemistry, pharmacology and validated assays for U.S. FDA approved COVID-19 therapeutic agents
by: Miranda F. Kamal, et al.
Published: (2022-06-01)

Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives – current situation and perspectives
by: Adriana Tamburello, et al.
Published: (2020-04-01)

Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID‐19: An early phase 1 descriptive study
by: Ricardo Aguilar, et al.
Published: (2024-03-01)